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A B S T R A C T
Pregnancy in women with severe mental illness is associated with adverse outcomes for mother and infant. There
are limited data on prevalence and predictors of relapse in pregnancy. A historical cohort study using anon-
ymised comprehensive electronic health records from secondary mental health care linked with national ma-
ternity data was carried out. Women with a history of serious mental illness who were pregnant (2007–2011),
and in remission at the start of pregnancy, were studied; severe relapse was deﬁned as admission to acute care or
self-harm. Predictors of relapse were analysed using random eﬀects logistic regression to account for repeated
measures in women with more than one pregnancy in the study period. In 454 pregnancies (389 women) there
were 58 (24%) relapses in women with non-aﬀective psychoses and 25 (12%) in women with aﬀective psychotic
or bipolar disorders. Independent predictors of relapse included non-aﬀective psychosis (adjusted OR=2.03;
95% CI= 1.16–3.54), number of recent admissions (1.37; 1.03–1.84), recent self-harm (2.24; 1.15–4.34),
substance use (2.15; 1.13–4.08), smoking (2.52; 1.26–5.02) and non-white ethnicity (black ethnicity: 2.37; 1.23-
4.57, mixed/other ethnicity: 2.94; 1.32-6.56). Women on no regular medication throughout ﬁrst trimester were
also at greater risk of relapse in pregnancy (1.99; 1.05–3.75). There was no interaction between severity of
illness and medication status as relapse predictors. Therefore, women with non-aﬀective psychosis and higher
number of recent acute admissions are at signiﬁcant risk of severe relapse in pregnancy. Continuation of
medication in women with severe mental illness who become pregnant may be protective.
1. Introduction
Relapse of serious mental illness (SMI; schizophrenia, related de-
lusional disorders, aﬀective psychoses and bipolar disorder) in the
perinatal period is potentially devastating for a woman and her unborn
baby. It may impact on her ability to care for herself, and rarely but
tragically result in custody loss of children, suicide or infanticide (Jones
et al., 2014). International conﬁdential enquiries into maternal deaths
highlight psychiatric illness as a leading cause (Austin et al., 2007;
Cantwell et al., 2011; Khalifeh et al., 2016).
Studies have consistently reported increased risk of relapse of psy-
chosis in the early postpartum, with risk factors including history of
bipolar disorder or post-partum psychosis (Jones et al., 2014; Munk-
Olsen et al., 2009; Wesseloo et al., 2015). There are fewer data on the
course of SMI during pregnancy, particularly for schizophrenia. Re-
cently reported data indicated a 12% rate of hospitalisation for women
with schizophrenia in pregnancy (Rochon-Terry et al., 2016). For bi-
polar disorder some studies estimate around 8–18% relapse in preg-
nancy (Di Florio et al., 2013; Grof et al., 2000), but tertiary perinatal
mental health clinics have reported substantially higher rates (71%),
particularly in women who discontinue medication (86%) and those
with more severe illness (Viguera et al., 2007). Varying deﬁnitions of
relapse may explain inconsistencies; some use hospital admission and
others use clinical or research interviews to determine symptoma-
tology, which identify less severe relapses.
We aimed to investigate risk and predictors of severe relapse in
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pregnancy in a cohort of women with SMI. We hypothesised that: 1)
diagnosis and markers of severity (non-aﬀective SMI, recent admis-
sions) and 2) ﬁrst trimester medication changes (switching or dis-
continuation) would be independently associated with relapse. We also
explored interactions between diagnosis, admissions in two years be-
fore pregnancy and domestic violence (DV) with medication.
2. Methods
2.1. Data source
Data came from the South London and Maudsley (SLaM) NIHR
Biomedical Research Centre Clinical Record Interactive Search (CRIS)
(Stewart et al., 2009), a large resource of comprehensive secondary
mental health records from over 300,000 patients. SLaM serves a
catchment of around 1.2 million residents from four London boroughs,
and provides some tertiary services. CRIS allows searching and retrieval
of anonymised clinical records within robust technical and procedural
safeguards (Fernandes et al., 2013). Data can be extracted from free text
(e.g. case notes and correspondence), using targeted keyword searches.
Structured data include socio-demographics (including ethnicity), year
and month of birth, and referrals data including admissions to SLAM
and movements within SLaM services such as wards and community
teams. Several natural language processing (NLP) applications on a
General Architecture for Text Engineering (GATE) platform
(Cunningham et al., 2013) have been developed which derive struc-
tured data from free text and are validated against manual annotations.
These include diagnosis and medication (Perera et al., 2016). CRIS was
approved for research by Oxfordshire Research Ethics Committee C
(08/H0606/71 + 5), and is linked to Hospital Episode Statistics: na-
tional data for inpatient, outpatient and accident and emergency at-
tendances in England including maternity data (NHS Digital, formerly
The Health Social Care Information Centre).
2.2. Study population
A historic cohort was assembled of women pregnant from 2007 to
2011 whose pregnancies continued beyond ﬁrst trimester. We used
maternity Hospital Episode Statistics (HES) indicating delivery of a
baby linked to CRIS data indicating women with SMI, using ICD-10
diagnoses F20, F22, F23, F25, F28, F29 (schizophrenia and related
disorders, schizoaﬀective disorders and delusional disorders), F30, F31
(mania and bipolar disorders), F32.3, F33.3 (psychotic depression),
F53.1 (puerperal psychosis). CRIS data is complete from 2006 and at
the time of data extraction, HES data was available up to the end of
2011. HES data indicated the end date of pregnancy. In order to collect
time dependent variables, trimesters of pregnancy were dated using a
modiﬁed validated algorithm (Li et al., 2013; Taylor et al., 2015). CRIS
data captured socio-demographic and clinical details regarding wo-
men's mental health. In order to be able to capture clinical details re-
garding women's mental health in the perinatal period, we included
women under SLaM care (therefore on CRIS) at any point from 6
months before to 6 weeks after the HES delivery episode with SMI di-
agnoses during the preconception period so. We excluded women
whose illness was not in remission at the start of pregnancy, determined
by admission to acute mental health care (inpatient or home treatment)
in the three months before the start date of pregnancy.
2.3. Measures
2.3.1. Severe relapse
The ﬁrst severe relapse of SMI (hereafter termed relapse) occurring
during pregnancy was measured. This has previously been deﬁned as
hospitalisation (Wesseloo et al., 2015). We deﬁned it as admission to
mental health inpatient care, referral for home treatment (services for
acute mental health crisis in the UK, involving frequent home visits
(Johnson et al., 2008)) or an episode of self-harm (see (Taylor et al.,
2016)) so that all signiﬁcant relapses were included. Admissions/re-
ferrals were extracted from structured CRIS data or HES inpatient ad-
missions to mental health trusts outside SLaM. Self-harm during preg-
nancy was extracted using free text search terms previously validated in
CRIS (Polling et al., 2015; Taylor et al., 2016).
2.3.2. Socio-demographic characteristics for index (ﬁrst) pregnancy
Recorded ethnicity was categorised into ‘Black African/Caribbean/
other’, ‘White British/other’, and ‘Mixed, Asian or other/not stated’.
Neighbourhood-level deprivation score was extracted closest in date to
the beginning of pregnancy. These give a summary measure of socio-
economic status at the level of the lower super output area (LSOA): a
geographic unit containing a minimum of 1000 residents and 400
households with an average nationally of around 1500 residents (Noble
et al., 2007). Manual searches of CRIS free text using piloted terms
established number of children prior to pregnancy, relationship status
in pregnancy, history of childhood abuse and DV before/during preg-
nancy and family history of mental illness. Recorded smoking in preg-
nancy was extracted by manual free text searches using terms (Wu
et al., 2013).
2.3.3. Mental disorder characteristics and severity at the beginning of
pregnancy
Diagnosis recorded at the start of pregnancy, extracted from CRIS
structured ﬁelds and free text using an NLP application validated for
dementia (Perera et al., 2016), was categorised into non-aﬀective and
aﬀective. Non-aﬀective SMI comprised schizophrenia, related psy-
choses, delusional disorders and schizoaﬀective disorders. Aﬀective
SMI comprised bipolar disorder, psychotic depression and history of
postpartum psychosis. Where diagnosis was unclear, correspondence
was scrutinised by a researcher and clinician.
Number of days in acute mental health care in the two years before
pregnancy was extracted from CRIS (supplemented with HES for out-
side-SLaM care (Taylor et al., 2015)) and spells of acute care deﬁned as
periods of treatment in acute care (inpatient or home treatment) with at
most 7 days between discharge and readmission. Time since last major
episode was calculated from the beginning of the most recent ‘spell’ of
acute care in the 2 years prior to conception. Detention under the
Mental Health Act (involuntary admission) in the 2 years before preg-
nancy was extracted from structured ﬁelds and free text.
Manual free text searches of CRIS ascertained recorded alcohol and
drug use in pregnancy within the previous 2 years, supplemented by
substance misuse diagnoses from CRIS structured ﬁelds and an NLP
application. Baseline level of functioning was estimated from the
highest total adjusted score recorded in the two years before pregnancy
from the Health of the Nation Outcome Scale (HoNOS), a routinely
collected 12-item measure in UK mental health services of health and
social functioning of people with severe mental illness (Wing et al.,
1998) stored in CRIS.
2.3.4. Medication exposure in the ﬁrst trimester of pregnancy
Medication exposures were extracted from free text in CRIS, pri-
marily using an NLP application (validated for a number of anti-
psychotic agents (Kadra et al., 2015)) to extract structured indicators
describing medication during the ﬁrst trimester, supplemented by
manual text searches. The clinical documents were recalled and
manually coded for information on medications not already validated.
Stops, starts and switches in regular antipsychotics, mood stabilisers
and antidepressants were noted, including whether stops occurred
abruptly (over 1–14 days) or gradually (> 14 days). Where speed of
discontinuation was not speciﬁed, women were coded as stopping
abruptly. Recorded non-adherence to medication was categorised if
there was written concern about this. Two researchers rated medica-
tion, with consensus meetings to resolve uncertainties; a consecutive
(26 pregnancies) were rated for identiﬁcation of antipsychotic, mood
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stabiliser and antidepressant with inter-rater agreements of 97%. For
the main analysis, medication was categorised as ‘stopped or switched’
if a woman had a stop and/or switch in a regular medication, ‘con-
tinued’ if a woman continued a regular medication all the way through
the ﬁrst trimester and did not stop or switch a regular medication, and
‘no medication at start of pregnancy’ if a woman was not on any regular
medication at the start of 1st trimester. Further detail including ex-
posures to individual medications and medication types in 3 months
before pregnancy and 1st trimester is provided elsewhere (Taylor et al.,
2015).
2.4. Data analysis
Data were analysed using STATA 12. After initial descriptive ana-
lyses of women, subsequent analyses were carried out by pregnancy.
Incidence and timing (by trimester) of relapses during pregnancy were
reported for the whole sample and stratiﬁed by baseline diagnosis. To
account for non-independent data in women who contributed more
than one pregnancy during the study period, all subsequent statistical
analyses were carried out using random eﬀects logistic regression. Only
one indicator of acute mental health care before pregnancy – number of
admissions – was used in multivariable analyses following chi2 tests for
association between them to assess colinearity. We used purposeful
selection of variables (Bursac et al., 2008), and predictors with p≤ 0.2
from unadjusted analyses were added simultaneously to the model and
unadjusted and fully adjusted eﬀect sizes compared. Predictors with a
fully adjusted p-value of> 0.5 were removed from the ﬁnal model.
Given our main hypothesis around medication; we ran post-hoc ana-
lyses using chi2 tests to assess association of covariates with the med-
ication variable using the 3 category medication variable as an outcome
and random eﬀects logistic regression to look at the association of
medication with relapse, adjusted for each covariate separately to in-
vestigate confounding of the association with medication and relapse.
Following a post-hoc test for colinearity between smoking and harmful
substance use we ran the multivariable model excluding harmful
substance use. Since women on no medication may be non-adherent or
psychiatrically stable, we ran a test for the interaction of psychiatric
stability (admission in the 2 years before pregnancy) and medication on
relapse. Most research has investigated bipolar disorder so we also
tested the interaction of medication with diagnosis on relapse and ran
the analysis stratiﬁed by diagnostic group (aﬀective/non-aﬀective),
reclassifying medication into two categories – continued versus
stopped/switched/no medication. All interaction tests used the like-
lihood ratio.
A number of sensitivity analyses were carried out. To address issues
of reverse causality for medication change and relapse both occurring
in the ﬁrst trimester, pregnancies with ﬁrst trimester relapses were
excluded, followed by an evaluation, censoring pregnancies which
ended in the 2nd trimester. For comparability with other investigations
of admissions in pregnancy, a sensitivity analysis excluded self-harm
from the deﬁnition of relapse. To compare with previous studies on
stopping medication and stopping abruptly in pregnancy (Viguera
et al., 2007), women who switched a medication only were excluded
from the ‘stopped or switched’ group (statistical power was insuﬃcient
to analyse switching separately) and we further excluded those stop-
ping medication gradually. A further analysis excluded women with
possible non-adherence in case of misclassiﬁcation and we also re-
classiﬁed women who continued a medication but were coded non-
adherent into the stopped/switched group. Finally we looked at the
unadjusted and adjusted associations with stopping versus switching/
continuing an antidepressant, mood stabiliser and antipsychotic sepa-
rately.
3. Results
3.1. Sample characteristics
There were 454 pregnancies in 389 women with history of SMI
(Fig. 1). Fifty-two (13.4%) women had more than one pregnancy in the
study period (number of pregnancies per woman ranged from 1 to 5).
Fig. 1. Identiﬁcation of women with SMI and pregnancies beyond ﬁrst trimester.
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Table 1 displays demographic and clinical characteristics of women. Of
203 (52.2%) women with diagnoses of non-aﬀective SMI, 112 (28.8%)
had diagnoses of schizophrenia or delusional disorder, 27 (6.9%) with
schizoaﬀective disorder and 64 (16.5%) had other non-aﬀective diag-
noses including acute and transient psychosis; 186 (47.8%) women had
aﬀective diagnoses including bipolar disorder (138 women, 35.5%),
depressive psychosis (41 women, 10.5%) and history of postpartum
psychosis (7 women, 1.8%). Comorbid diagnoses between 9 months
and 2 years before delivery episode included 18 (4.6%) women with
substance use diagnoses, 9 (2.3%) with personality disorder diagnoses,
11 (2.8%) with anxiety disorders, 6 (1.5%) with learning diﬃculties
and<5 with other diagnoses including eating disorders, conduct dis-
orders and epilepsy.
In 454 pregnancies, there were 83 (18.3%) relapses, including 74
(16.3%) admissions to acute care (inpatient or home treatment), with
26 (5.7%) relapses occurring in the ﬁrst trimester and 32 (7.5%) in the
second. Thirteen pregnancies ended in the second trimester, and of 383
remaining pregnancies a further 25 (6.5%) relapsed in third trimester.
All admissions to the mother and baby unit were for acute mental
health reasons. Supplementary Table 1 provides further detail on re-
lapses by trimester and diagnosis.
First trimester medication (antidepressant, mood stabiliser or anti-
psychotic) exposures were as follows: 147 (15.7%) no regular
medication, 240 (52.9%) receiving an antipsychotic, 67 (14.8%) a
mood stabiliser and 106 (23.4%) an antidepressant; 188 (41.4%) ex-
posed to one agent only, 88 (19.3%) exposed to two and 31 (6.8%) to
more than two. Table 1 shows medication categories in the 1st trimester
as used for analysis. Medication categories were associated strongly
from one trimester to the next; from 3 months before pregnancy to 1st
trimester, chi2= 312.64, p < 0.001, from 1st to 2nd trimester,
chi2= 296.41, p < 0.001 and from 1st to 3rd trimester,
chi2= 182.34, p < 0.001.
Deprivation scores were missing for 18 (4.0%) pregnancies. HoNOS
scores were missing for 212 (46.7%).
3.2. Socio-demographic and clinical characteristics associated with relapse
in pregnancy (Table 2) and associated with medication exposures
(supplementary table 2)
Relapse in pregnancy was signiﬁcantly associated with non-white
ethnicity, DV, smoking, non-aﬀective psychosis, substance misuse, ad-
missions in the two years before pregnancy, less than 2 years since
previous acute admission, and self-harm in the 2 years before preg-
nancy. Very similar results were found when relapses in the 1st tri-
mester were excluded. Women who continued to take medication had
fewer relapses than women who were medication free or stopped/
switched medication but this was not statistically signiﬁcant. Age,
history of admissions variables, self-harm and smoking in pregnancy
were distributed diﬀerently across medication groups. Average age was
highest in the continued medication group. Women with pregnancies
unexposed to medication tended to have less admissions or time in
acute care in the two years before pregnancy. Rates of self-harm were
highest in those who stopped or switched a medication and lowest in
those who continued. Recorded smoking was highest in those who
stopped or switched medication and lowest in those unexposed to
medication at the beginning of pregnancy.
3.2.1. Multivariable analysis
In the fully adjusted model (Table 3), (adjusted for medication
group, admissions and self-harm in 2 years before pregnancy, diagnosis
at baseline, harmful substance use, smoking in pregnancy and ethni-
city) relapse was independently associated with non-aﬀective psy-
chosis, illness severity (admissions and self-harm in two years before
pregnancy), substance misuse, smoking in pregnancy and non-white
ethnicity. Given substance misuse and smoking were strongly asso-
ciated (p < 0.001), we also ran the model excluding substance misuse,
which made no diﬀerence to our ﬁndings. Women not on medication
were more likely to relapse than women who continued medication;
stopping or switching medication was not associated with increased risk
of relapse (Tables 3 and 4). However, when ﬁrst trimester relapses were
excluded, the association between being on no medication and relapse
was attenuated (adjusted OR=1.43; 95%CI 0.69–2.98). Post-hoc
analysis showed the association with relapse was most confounded by
admissions in 2 years before pregnancy and smoking (Supplementary
Table 3). Stratiﬁed by aﬀective/non-aﬀective diagnosis (Supplementary
Table 4), ﬁndings were similar, though due to smaller numbers most
associations did not reach statistical signiﬁcance. No signiﬁcant inter-
actions were found on risk of relapse between medication and aﬀective/
non-aﬀective diagnosis (chi2=0.01, p=0.922) and medication and
admissions in the 2 years before pregnancy (chi2=0.52, p=0.471), or
between DV and medication status (chi2= 1.34, p=0.248).
3.3. Sensitivity analyses
Deﬁning relapse by acute admissions only (n= 74 relapses) made
little diﬀerence to results. Excluding pregnancies where medication was
stopped gradually (n=13) made no meaningful diﬀerence (Table 4).
Excluding those with recorded non-adherence to address potential
misclassiﬁcation of medication (17 pregnancies) strengthened the
Table 1
Socio-demographic and clinical characteristics of 389 pregnant women with
severe mental illness.
N=389
Diagnosis at beginning of pregnancy, N (%)
Aﬀective 186 (47.8)
Non aﬀective 203 (52.2)
Ethnicity, N(%)
White British & other White 132 (33.9)
Black African & other Black 188 (48.3)
Asian/Mixed/Other 69 (17.7)
Deprivation score, median(range)1 34.9 (4.8,61.5)
Maternal age at 1st index delivery, mean(SD), 31.8 (6.1)
Partner during 1st index pregnancy 269 (69.2)
Number of children at 1st index pregnancy, N(%)
0 182 (46.8)
1 103 (26.5)
≥2 104 (26.7)
Recorded history of child abuse, N(%) 78 (20.1)
Recorded domestic abuse before/during pregnancy, N(%) 133 (34.2)
Smoking in pregnancy, N(%) 69 (17.7)
Harmful substance use, N(%) 96 (24.7)
Self-harm in 2 years before pregnancy, N(%) 54 (13.9)
Number of days of acute care in 2 years before pregnancy, N(%)
0 235 (60.4)
1-30 53 (13.6)
31-60 43 (11.1)
61+ (−537) 58 (14.9)
Number of acute admissions in 2 years before pregnancy, N(%)
0 235 (60.4)
1 103 (26.5)
2 30 (7.7)
> 2 21 (5.4)
Time since last acute admission, N(%)
None in 2 years before pregnancy 235 (60.4)
1 year 79 (20.3)
2 years 75 (19.3)
MHA3 in 2 years before pregnancy, N(%) 67 (17.2)
Highest HoNOS total adjusted score in 2 years before
pregnancy, median (range)2
12 (0–36)
Family history of any mental illness, N(%) 168 (43.2)
Medication changes 1st trimester, N(%)
Continued 145 (37.3)
Stopped and/or switched 105 (27.0)
No medication at start 139 (35.7)
1: n= 374, 2: n= 196, 3: detained under section 2 or 3 of the mental health
act.
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Table 2
Socio-demographic and clinical characteristic, and associations with relapse in pregnancy episodes (n= 454).
N N (%) relapse in pregnancy (n= 83) Odds ratio (95% CI) p-value
Baseline Diagnosis
Aﬀective 216 25 (11.6) Ref
Non aﬀective 238 58 (24.4) 2.58 (1.45,4.58) 0.001*
Ethnicity
White British & other White 221 49 (22.2) Ref
Black African & other Black 154 17 (11.0) 2.50 (1.24,5.04) 0.010*
Asian/Mixed/Other 79 17 (21.5) 2.31 (1.01,5.25) 0.047*
Partner during pregnancyb 321 58 (18.1) 0.94 (0.53,1.65) 0.826
Children at index pregnancy
0 188 35 (18.6) Ref
1 127 25 (19.7) 1.06 (0.58,1.98) 0.836
≥2 139 23 (16.6) 0.83 (0.44,1.57) 0.563
Victim of child abuseb 96 22 (22.9) 1.44 (0.80,2.60) 0.221
Victim of domestic abuse before or during pregnancyb 167 39 (23.4) 1.74 (1.02,2.98) 0.044*
Smoking in pregnancyb 79 31 (39.2) 4.47 (2.23,8.99) < 0.001*
Harmful substance useb 109 36 (33.0) 3.37 (1.82,6.21) < 0.001*
Self-harm in 2 years before pregnancyb 61 23 (37.7) 3.60 (1.83,7.10)* < 0.001*
Number of days of acute care in 2 years before pregnancy,
0 270 38 (14.1) Ref
1-30 65 18 (27.7) 2.34 (1.22,4.48)* 0.010*
31-60 46 8 (17.4) 1.28 (0.56,2.97)a 0.558*
61+ 73 19 (26.0) 2.15 (1.15,4.02) 0.017
Linear association 454 83 (18.3) 1.01 (1.00,1.02)* 0.091
Number of acute admissions in 2 years before pregnancy
0 270 38 (14.1) Ref
1 121 25 (20.7) 1.59 (0.91,2.79) 0.107
2 39 11 (28.2) 2.40 (1.10,5.26)* 0.029*
>2 24 9 (37.5) 3.67 (1.47,9.25)* 0.005*
Linear association 454 83 (18.3) 1.55 (1.20,2.01)* < 0.001*
MHAa 2 years before pregnancyb 77 16 (20.8) 1.18 (0.61,2.28) 0.663
Time since last admission (years)
Not in 2 years before pregnancy 270 38 (14.1) Ref
< 1 year 99 30 (30.3) 2.66 (1.53,4.63) 0.001*
1–2 years 85 15 (17.7) 1.31 (0.68,2.52) 0.425
Family history of mental illnessb 199 40 (20.1) 1.23 (0.74,2.04) 0.432
Medication change 1st trimester
Continued/no stop or switch 173 25 (14.5) Ref
Stopped and/or Switched 118 25 (21.2) 1.66 (0.85,3.26) 0.140
No medication 163 33 (20.3) 1.60 (0.84,3.06) 0.153
Deprivation score (per unit increase), (n= 436) 1.02 (0.99,1.04) 0.147
Maternal age at delivery (per year increase), (n= 454) 0.96 (0.92,1.01) 0.091
Highest HoNOS total adjusted score in 2 years before pregnancy (per unit increase), n= 242 1.01 (0.97,1.06) 0.599
a Detained under section 2 or 3 of the Mental Health Act; *p < 0.05.
b For partner during pregnancy, victim of child/domestic abuse, smoking/harmful substance use, MHA admission and family history of mental illness variables,
the reference group was ‘no’ and ‘absent information’ combined.
Table 3
Multivariable analysis of predictors of relapse in pregnancy.
Relapse in pregnancy,
odds ratios (95% CI); N= 454, n= 83 relapses
Relapse in 2nd or 3rd trimester,
odds ratios (95% CI); N= 428, n= 57 relapses
Unadjusted Fully adjusted Unadjusted Fully adjusted
Medication
Continuation Ref Ref Ref Ref
Stopped/switched 1.66 (0.85,3.26), 0.140 1.30 (0.66,2.58), 0.446 1.41 (0.67,2.95), 0.363 1.16 (0.55,2.45), 0.703
No medication 1.60 (0.84,3.06), 0.153 1.99 (1.05,3.75), 0.034 1.01 (0.49,2.09), 0.977 1.43 (0.69,2.98), 0.335
Number of admissions in last 2 years 1.55 (1.20,2.01), 0.001 1.37 (1.03,1.84), 0.033 1.68 (1.26,2.23), < 0.001 1.49 (1.08,2.05),0.015
Non-aﬀective diagnosis at baseline 2.58 (1.45,4.58), 0.001 2.03 (1.16,3.54), 0.013 2.55 (1.35,4.81),0.004 2.06 (1.08,3.94),0.028
Self-harm in last 2 years 3.60 (1.83,7.10), < 0.001 2.24 (1.15,4.34), 0.017 3.25 (1.38,7.66),0.007 1.87 (0.87,4.03), 0.109
Harmful Substance use 3.37 (1.82,6.21), < 0.001 2.15 (1.13,4.08), 0.019 2.83 (1.37,5.83),0.005 1.59 (0.74,3.41), 0.231
Smoking in pregnancy 4.47 (2.23,8.99), < 0.001 2.52 (1.26,5.02), 0.009 4.11 (1.83,9.22), 0.001 2.72 (1.21,6.09), 0.015
Ethnicity
White Ref Ref Ref Ref
Black 2.50 (1.24,5.04), 0.010 2.37 (1.23,4.57), 0.010 2.92 (1.31,6.50), 0.009 2.79 (1.26,6.18), 0.014
Mixed/Other 2.31 (1.01,5.25), 0.047 2.94 (1.32,6.56), 0.008 2.65 (1.04,6.77), 0.042 3.29 (1.27,8.53), 0.014
Based on predictors with p < 0.2 from bivariate analysis. Maternal age at delivery, deprivation score and domestic abuse were removed from the ﬁnal model as they
had a fully adjusted p > 0.5.
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unadjusted diﬀerence between continuing vs. stopping/switching
medication, but multivariable output remained similar (Supplementary
Table 5). Exclusion of 14 pregnancies which ended in 2nd trimester
made no diﬀerence (Supplementary Table 6). There was no association
between these early ending pregnancies and relapse (Fisher's exact,
p= 0.482). Women who stopped an antipsychotic had higher odds of
relapse than women who continued/switched, but this was not the case
for mood stabilisers or antidepressants. However these ﬁndings were
not signiﬁcant (Supplementary Table 7).
4. Discussion
In 389 women with SMI, there were 83 (18.3%) relapses during 454
pregnancies – 58 (24.4%) in pregnancies of women with non-aﬀective
diagnoses and 25 (11.6%) in women with aﬀective disorders. Based on
multivariable analyses, the nature and severity of the mental disorder
(non-aﬀective psychosis at baseline, recent admissions, harmful sub-
stance use, and recent self-harm) was associated with relapse in preg-
nancy. Smoking and non-white ethnicity also independently predicted
relapse. Continuing medication compared with not taking medication
at the beginning of pregnancy was protective, but we were unable to
draw conclusions about switching or stopping medication in the ﬁrst
trimester.
These ﬁndings provide some reassurance that although relapse can
occur in pregnancy, most women in this cohort did not have episodes
needing acute care or manifesting as self-harm. Our ﬁndings suggest
that risk of relapse in women with bipolar disorder may be lower than
in studies of women attending specialist clinics (Viguera et al, 2007,
2011), and comparable with the few studies carried out on more re-
presentative samples (Judd et al., 2014). There are few data in women
with non-aﬀective psychoses. One other large study to date, which used
administrative data, found that 24% of pregnant women with schizo-
phrenia were admitted or visited a mental health emergency service,
which is comparable to our ﬁndings (Vigod et al., 2014).
There has been little previous research into risk factors for relapse of
severe mental disorder in pregnancy, although associations with se-
verity of the pre-existing psychiatric illness have been reported (Munk-
Olsen et al., 2009; Vigod and Ross, 2010; Viguera et al., 2007). Using
comprehensive clinical data we found that smoking, recent self-harm
and substance misuse also showed associations with relapse, potentially
suggesting higher-risk lifestyles. Such women may ﬁnd it more diﬃcult
to prioritise stopping smoking or substance use in pregnancy; alter-
natively, smoking and substance misuse may be associated with
worsening mental health. Both are important risk factors for adverse
fetal outcomes (Stein et al., 2014), which need to be addressed by
services. Being of black ethnicity was also associated with increased risk
of relapse in pregnancy, consistent with research showing higher rates
of relapse and worse outcomes in people of black compared with white
ethnicity (Mann et al., 2014). Non-aﬀective diagnosis has also been
associated with worse outcomes in patients with psychosis (Morgan
et al., 2014) as well as non-adherence to medication (Porcelli et al.,
2016). Relapse or psychiatric admission in pregnancy may be an im-
portant predictor of relapse postpartum and further work with this
cohort has looked at relapse in the ﬁrst three months postpartum in-
cluding admission in pregnancy as a predictor.
We did not ﬁnd an association between medication discontinuation
or switching and relapse, in contrast to others (Viguera et al., 2007)
who found 86% risk in women with bipolar disorder stopping mood
stabilising medication compared with 37% in women who continued,
independent of disorder severity measures. Diﬀerent deﬁnitions of re-
lapse may explain some of this heterogeneity. In Viguera's study, it
could not be determined whether medication change in the ﬁrst tri-
mester occurred before or after a relapse in early pregnancy; however,
excluding women who relapsed in the ﬁrst trimester attenuated our
association, and indeed Viguera's data showed particularly high risk of
relapse in early pregnancy. In observational research, independent ef-
fects of psychiatric illness and medication can be challenging to dis-
entangle. Diﬀerent classiﬁcation of medication exposures may also ex-
plain some discrepancy in ﬁndings. Viguera investigated stopping mood
stabilisers from 6 months before to 12 weeks after conception and ex-
cluded women who stopped medication over 6 months before. In our
data women who stopped medication before pregnancy would be in the
‘no medication’ group and tended to relapse early.
To our knowledge, there are no comparative data in pregnant
women with schizophrenia; however, outside the perinatal period,
switching medication appears well tolerated (Roussidis et al., 2013).
These clinical records enabled us to investigate potential impact of
other moderators, notably DV. This needs replication in larger samples
but its potential adverse impact on mental health is reported elsewhere
(Khalifeh et al., 2015) as is the importance of addressing DV perinatally
(NICE, 2014).
A major strength of this study was the novel methodology using
electronic secondary mental health data. This allowed investigation of a
larger cohort of women than previous clinical studies, with more detail
on illness severity and other psychosocial characteristics than popula-
tion registries. SLaM provides near-monopoly secondary mental health
Table 4
Sensitivity analyses to investigate stopping medication in 1st trimester.
Excluding pregnancies with only a switch in medication,
odds ratios (95% CI); N=436, n= 79 relapses
Stopping medication abruptly (excluding only switchers and gradual stoppers),
odds ratios (95% CI); N= 422, n= 75 relapses
Unadjusted Fully adjusted Unadjusted Fully adjusted
Medication
Continued Ref Ref Ref Ref
Stopped 1.65 (0.81,3.37), 0.170 1.30 (0.63,2.68), 0.475 1.48 (0.70,3.11), 0.302 1.16 (0.53,2.53), 0.704
No medication at start 1.61 (0.84,3.10), 0.152 1.99 (1.03,3.84), 0.040 1.62 (0.85,3.11), 0.146 2.09 (1.06,4.13), 0.033
Number of admissions in 2 years
before
1.52 (1.16,2.00), 0.003 1.39 (1.03,1.88), 0.034 1.52 (1.16,2.00), 0.003 1.40 (1.02,1.93), 0.038
Baseline diagnosis 2.56 (1.41,4.63), 0.002 1.99 (1.12,3.53), 0.019 2.56 (1.41,4.63), 0.002 2.01 (1.10,3.68), 0.023
Self-harm in 2 years before
pregnancy
3.01 (1.49,6.08), 0.002 2.12 (1.05,4.28), 0.039 3.01 (1.49,6.08), 0.002 2.08 (1.00,4.35), 0.051
Harmful substance use 2.95 (1.57,5.54), 0.001 2.01 (1.02,3.95), 0.042 2.95 (1.57,5.54), 0.001 1.97 (0.96,4.03), 0.063
Smoking 4.28 (2.06,8.89), < 0.001 2.44 (1.16,5.10), 0.018 4.28 (2.06,8.89), < 0.001 2.75 (1.24,6.09), 0.012
Ethnicity
White Ref Ref Ref Ref
Black 3.16 (1.43,6.98), 0.022 2.54 (1.20,5.38), 0.015 4.18 (1.72,10.19),0.002 3.40 (1.45,8.00), 0.005
Mixed/Other 2.84 (1.16,6.96), 0.005 3.12 (1.33,7.35), 0.009 3.52 (1.33,9.34), 0.012 4.21 (1.61,11.00),0.003
Based on predictors with p < 0.2 from bivariate analysis. Maternal age at delivery, deprivation score and domestic abuse were removed from the ﬁnal model as they
had a fully adjusted p > 0.5.
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services to its catchment, so these data are likely to include most
pregnant women with SMI in this locality. The linkage with HES en-
abled us to collect psychiatric admissions data covering England,
minimising loss to follow-up and giving a full picture of illness history
for this dynamic cohort. We were also able to collect data on recorded
DV, substance use and self-harm. Detailed clinical data on medication
enabled us to capture changes resulting from mutual decisions made
under clinical guidance (Swanson et al., 2015) or self-initiated cessation
decisions, as well as recorded adherence, so we were able to address
some misclassiﬁcations not achievable with registry data. CRIS data are
not collected for research and rely on accuracy and comprehensiveness
of clinical note keeping. Although we used multiple validated search
terms, some information may be absent or underreported, such as that
on smoking. We were not able to ascertain previous history of perinatal
episodes which have been shown predictive of postpartum relapse.
However, this methodology enabled us to observe this high-risk group
of pregnant women in a real-world setting. We were able to include self-
harm and women potentially more severely at risk than may take part
in clinical studies.
Considering sample selection, our data source does not include
women managed only in primary care. However, the threshold for re-
ferral to secondary care may be lower in pregnancy, and national
guidelines (NICE, 2014) recommend referral of pregnant women with
SMI history to secondary mental health care. There may also be selec-
tion into pregnancy in women with SMI, since reported fertility is lower
than that in the general population (Howard et al., 2002; Vigod et al.,
2012). Schizophrenia may aﬀect relationship stability (Howard, 2005)
and there are also reported higher rates of termination (Laursen and
Munk-Olsen, 2010) and unplanned pregnancies in women with SMI
(Miller and Finnerty, 1996). These factors aﬀect comparability with
times outside pregnancy. The linkage to HES data allowed a robust
method of identifying pregnancies, covering deliveries across England.
Home births are thought to be under recorded in HES (2.4% of de-
liveries in England in 2011 were at home) (ONS, 2013) though preg-
nancies in women with SMI are considered high-risk obstetrically so
home births may be less likely. The retrospective design may have
identiﬁed a particularly severe group of women since by default women
admitted in pregnancy would have been included in the cohort. Women
also receive many diagnoses in the health records; therefore, potential
misclassiﬁcation may have aﬀected inclusion.
Considering the outcome, admission to acute care may not be a
sensitive indicator of relapse, as less severe relapses may be managed by
the secondary services already providing care, or by medication
changes. Whilst using this endpoint may have missed some cases of
relapse, it may also have included women admitted for social reasons,
thus reﬂecting socio-economic disadvantage rather than relapse per se.
However, all admissions to the MBU during pregnancy were for acute
illness so this is unlikely to have skewed the results signiﬁcantly. We did
not carry out survival analyses as dates of admission were considered to
be insuﬃciently accurate estimates of end-point timing.
Considering exposures, the stopped/switched medication group
may be heterogeneous in terms of reasons for stopping/switching.
However most women who stopped medication in the ﬁrst trimester did
so because of pregnancy (Taylor et al., 2015) and sensitivity analyses
excluding switchers and gradual stoppers made little diﬀerence to
ﬁndings. We did not have the power to analyse gradual stoppers se-
parately and there may have been some misclassiﬁcation of speed of
stopping medication as it was diﬃcult to determine from the clinical
notes and we assumed abrupt stopping unless stated otherwise. Pre-
vious research has shown that women with bipolar disorder may have
higher risk of relapse if they discontinue or do not take medication.
Women with non-aﬀective psychosis may not be the same. However we
did not have a large enough sample to ascertain predictors or mod-
erators of relapse separately in the non-aﬀective and aﬀective groups.
The fairly small proportion of relapses detected limited statistical power
to detect some associations, and larger cohorts would be needed to
address some remaining questions. Prospective clinical research could
address some of the issues of unrecorded clinical information although
assembling a large cohort would be costly and time-consuming with
higher risk of attrition bias.
5. Conclusions
Women with indicators of more severe SMI are more likely to re-
lapse in pregnancy, these indicators include having more admissions in
the two years prior to pregnancy, non-aﬀective illness, history of self-
harm, smoking and substance use. We found weaker evidence of asso-
ciation with medication change but women on no medication at the
start of pregnancy were more likely to relapse in early pregnancy. While
the risks and beneﬁts of taking medication in pregnancy must be
weighed up for each individual (NICE, 2014) this study has identiﬁed
those at particularly high risk of relapse in pregnancy – evidence that
could be shared with women who are making decisions about medi-
cation in pregnancy. Women with SMI have multiple risk factors for
adverse pregnancy outcomes including risk of relapse, smoking, sub-
stance use, medication and should be under care of specialist services
during pregnancy. Attention should also be paid to potentially mod-
iﬁable risk factors including smoking and substance use.
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